MedTrace Logo

Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer

NCT06589609 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-09-19

No results posted yet for this study

Summary

A clinical study of an immunotherapy in patients with head or neck cancers associated with the HPV16 virus

Conditions

  • Oropharyngeal Squamous Cell Carcinoma (SCC)

Interventions

BIOLOGICAL

FluBHPVE6E7

Intratumoral administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule.

Sponsors & Collaborators

  • BlueSky Immunotherapies GmbH

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-23
Primary Completion
2027-11-30
Completion
2029-11-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06589609 on ClinicalTrials.gov